Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance
Reference number: TA269
Published: 12 December 2012
Last updated: 01 January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix A - provisional matrix of stakeholders

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix A - provisional matrix of stakeholders

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix A - provisional matrix of stakeholders
17 November 2014
(99.44 Kb 28 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 17 November 2014